ASCEND GO-2: Study of RVT-1401 for the Treatment of Participants With Active, Moderate to Severe Graves' Ophthalmopathy ( GO )

ClinicalTrials.gov ID: NCT03938545

Public ClinicalTrials.gov record NCT03938545. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 5, 2026, 10:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

ASCEND GO-2: A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled Study of RVT-1401 for the Treatment of Patients With Active, Moderate to Severe Graves' Ophthalmopathy

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of the current study is to assess the efficacy and safety/tolerability of three dose regimens of RVT-1401 in the treatment of active, moderate to severe GO participants. In addition, the study is designed to characterize the effect of RVT-1401 exposure on reduction in anti-TSHR IgG

Study identification

NCT ID: NCT03938545
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 2
Lead sponsor: Immunovant Sciences GmbH; Industry
Enrollment: 65 participants

Conditions and interventions

Conditions

Graves' Ophthalmopathy (GO)

Interventions

Drug · Other

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jul 22, 2019
Primary completion: Feb 1, 2021
Completion: Apr 14, 2021
Last update posted: Sep 21, 2022

2019 – 2021

United States locations

U.S. sites: 12
U.S. states: 11
U.S. cities: 12

Facility	City	State	ZIP	Site status
Multispecialty Aesthetic Clinical Research Organziation (MACRO)	Beverly Hills	California	90212	—
Doheny Eye Center UCLA	Pasadena	California	91105	—
University of Miami Miller School of Medicine Bascom Palmer Eye Institute	Miami	Florida	33136	—
University of Iowa Hospitals & Clinics - Eye Clinic	Iowa City	Iowa	52242	—
University of Michigan - Kellogg Eye Center	Ann Arbor	Michigan	48105	—
Mayo Clinic	Rochester	Minnesota	55905	—
Washington University School of Medicine - Center for Advanced Medicine (CAM) - Eye Center	St Louis	Missouri	63146	—
University of Rochester Medical Center	Rochester	New York	14642	—
Oregon Health & Science University (OHSU) - Casey Eye Institute (CEI)-Marquam Hill	Portland	Oregon	97239	—
Eye Wellness Center	Houston	Texas	77005	—
Eyelid Center of Utah	Salt Lake City	Utah	84102	—
West Virginia University Eye Institute	Morgantown	West Virginia	26506	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 13 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT03938545, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 21, 2022 · Synced Sep 5, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03938545 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →